Search

for
Search:

Research

5 / 1000+ results

research Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study

December 2022 in “Journal of The American Academy of Dermatology”

This letter highlights the lack of evidence on managing persistent alopecia induced by chemotherapy and endocrine therapy in breast cancer patients, noting that prior studies have not included endocrine therapy-induced alopecia.

research Response to Kang et al, “Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study”

2 citations , December 2024 in “Journal of the American Academy of Dermatology”

Low-dose oral minoxidil combined with topical minoxidil improves hair density in breast cancer patients but may cause excess hair growth.

research Pattern Alopecia during Hormonal Anticancer Therapy in Patients with Breast Cancer

9 citations , January 2014 in “Annals of Dermatology”

In this report, five female patients undergoing hormonal anticancer therapy for breast cancer prevention developed pattern alopecia, which the authors attribute to androgen-estrogen imbalance caused by antiestrogenic drugs.

research Limitations of Treatment-Induced Alopecia Grading Instruments in Evaluating Therapeutic Response

April 2026 in “Academic Dermatology”

In this retrospective observational study, researchers found that the Dean Scale showed better diagnostic accuracy than the CTCAE scale for detecting clinician-reported therapeutic responses to minoxidil in patients with anticancer therapy-induced alopecia, but both scales had limitations in recording clinically significant hair regrowth.

research BROMELAIN AND FINASTERIDE COMBINATION THERAPY INDUCES HAIR REGROWTH IN ALOPECIA PARTICIPANTS

January 2025

In this randomized, double-blind study of 24 participants with hair loss, the combination of bromelain and finasteride increased hair count, thickness, and density significantly more than finasteride alone or a placebo cream, while reducing inflammatory markers.

View more "anticancer therapy-induced alopecia" in research →

Community Join

4 / 1000+ results

community Better Than Minoxidil? Topical Sodium Valproate

50 upvotes 1 year ago

Topical sodium valproate may promote hair growth by inhibiting GSK3β, allowing beta-catenin to proliferate, but it has potential side effects and requires more research. The conversation also mentions skepticism about a product called Vdphlo1, which includes sodium valproate and other ingredients.

community From Perfect Hair to This: 2 Years of Chronic TE + Unmasked AGA.

in Treatment 5 upvotes 5 months ago

A 25-year-old is experiencing chronic telogen effluvium (TE) and androgenetic alopecia (AGA) after surgery, using finasteride, red light therapy, and supplements, and considering oral minoxidil despite heart concerns. They are unsure whether to start minoxidil before or after an upcoming surgery, which may trigger another hair shed.

community can someone help me identify these pls

in Treatment 10 months ago

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

community Article of all potential future cures

25 upvotes 1 year ago

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

View more "anticancer therapy-induced alopecia" in community →

Learn

5 / 800 results

learn Baricitinib

JAK inhibitor pill used for severe alopecia areata

Baricitinib: How did a drug for arthritis end up helping people regrow hair from alopecia areata? Baricitinib, an arthritis drug, was FDA-approved in 2022 for adults with severe alopecia areata after trials in which about a third of patients on 4 mg regained most scalp hair. It carries an FDA boxed warning, and regrowth is usually lost when it is stopped.

learn Tofacitinib

What is tofacitinib, and why is it discussed in relation to autoimmune-related hair loss such as alopecia areata? Tofacitinib is a prescription JAK inhibitor approved for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis — not for alopecia areata. It is discussed for hair loss because a 2014 case report and a 2016 open-label trial reported regrowth in severe alopecia areata, but that use is off-label, the regrowth relapsed after stopping, and the drug carries an FDA boxed warning.
What types of hair loss conditions are most commonly associated with tofacitinib use in clinical settings? Published studies link tofacitinib mainly to alopecia areata and its severe variants — as an off-label drug being studied for them, not as a cause of hair loss. The evidence is mostly small, open-label or retrospective, and relapse after stopping is commonly reported.
What are the key limitations and considerations surrounding tofacitinib in hair loss products and therapies? Reported hair regrowth with tofacitinib comes from alopecia areata, an autoimmune condition — mostly from small, non-randomized studies, with relapse common after stopping. There is no good evidence it helps pattern hair loss, and it is not approved for hair loss anywhere.

learn TDM-105795

What types of alopecia or hair loss conditions might TDM-105795 be designed to target based on current research? TDM-105795 has been studied only in men with androgenetic alopecia, in two Phase 1 studies and one 16-week Phase 2 trial. There is no research on it in women or in any other type of hair loss.

learn Alopecia Areata

autoimmune disorder causing patchy hair loss

learn retinoic acid

View more "anticancer therapy-induced alopecia" in learn →

Clinics

6 / 41 results

All 41 clinic results →

Experts

— no results

Try a deeper search in experts →